abacavir/dolutegravir/lamivudine dispersible and immediate-release tablets
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for abacavir/dolutegravir/lamivudine dispersible and immediate-release tablets, covering 2023-02-13 to 2023-02-13. Get the full timeline:
Most recent: Clinical Trial Update: The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age [Phase 1, Phase 2]